Journal article

Efficacy of dual carbapenem treatment in a murine sepsis model of infection due to carbapenemase-producing Acinetobacter baumannii

  • Cebrero-Cangueiro, T. Institute of Biomedicine of Seville (IBi, S), Virgen del Rocio University Hospital/CSIC/University of Seville, Seville, Spain - Department of Medicine, University of Seville, Seville, Spain
  • Nordmann, Patrice Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg, Switzerland - INSERM European Unit (LEA-IAME, France), University of Fribourg, Fribourg, Switzerland - National Reference Center for Emerging Antibiotic Resistance, University of Fribourg, Fribourg, Switzerland - University of Lausanne and University Hospital Center, Lausanne, Switzerland
  • Carretero-Ledesma, M. Institute of Biomedicine of Seville (IBi, S), Virgen del Rocio University Hospital/CSIC/University of Seville, Seville, Spain - Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine, Virgen del Rocio University Hospital, Seville, Spain
  • Pachón, J. Institute of Biomedicine of Seville (IBi, S), Virgen del Rocio University Hospital/CSIC/University of Seville, Seville, Spain - Department of Medicine, University of Seville, Seville, Spain
  • Pachón-Ibáñez, M. E. Institute of Biomedicine of Seville (IBi, S), Virgen del Rocio University Hospital/CSIC/University of Seville, Seville, Spain - Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine, Virgen del Rocio University Hospital, Seville, Spain
Show more…
    23.11.2020
Published in:
  • Journal of Antimicrobial Chemotherapy. - 2020, p. dkaa487
English Objectives: To evaluate the in vivo efficacy of a dual carbapenem combination containing imipenem plus meropenem against carbapenem-resistant Acinetobacter baumannii producing carbapenemases OXA-23 or OXA-58.Methods: An experimental model of peritonitis using C57BL/6J female mice was developed and the minimum lethal doses were calculated for infections due to OXA-23 or OXA-58 producers of A. baumannii clinical isolates. The efficacies of the carbapenems in monotherapy and in combination were tested.Results: Meropenem was better than imipenem in mice infected with either of the carbapenem-resistant A. baumannii (CRAb) strains. The combination of meropenem plus imipenem significantly improved the clearance of CRAbs from spleen compared with non-treated groups. The carbapenem-containing combination was better than imipenem for treating mice infected with both carbapenemase producers. In blood, the carbapenem combination significantly decreased the bacterial load of the OXA-23 producers compared with imipenem or meropenem used in monotherapy.Conclusions: These results suggest that dual carbapenem combination could be an option for the treatment of infections due to carbapenemase-producing A. baumannii such as OXA-23 and OXA-58 producers.
Faculty
Faculté des sciences et de médecine
Department
Médecine 3ème année
Language
  • English
Classification
Biology
License
License undefined
Identifiers
Persistent URL
https://folia.unifr.ch/unifr/documents/309240
Statistics

Document views: 7 File downloads:
  • nor_edc.pdf: 1